

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3974040
<b>Application Number:</b>	10657363
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3135
<b>Title of Invention:</b>	Ultra high affinity neutralizing antibodies
<b>First Named Inventor/Applicant Name:</b>	James F. Young
<b>Customer Number:</b>	20583
<b>Filer:</b>	Tamera Weisser/Eric Baclig
<b>Filer Authorized By:</b>	Tamera Weisser
<b>Attorney Docket Number:</b>	10271-159-999
<b>Receipt Date:</b>	22-SEP-2008
<b>Filing Date:</b>	08-SEP-2003
<b>Time Stamp:</b>	20:02:44
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/Message Digest	Multi Part/.zip	Pages (if appl.)
1	NPL Documents	GLEZEN_J_Pediatr_708.pdf	663365 1d8b867e2c14dfbb38aa34d33547901396b 36df1	no	8

### Warnings:

### Information:

2	NPL Documents	GROOTHUIS_Pediatrics_199.pdf	574388 43df84ebd922546c058cd397c23bdacf825 10f71	no	5
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	GROOTHUIS_N_Engl_J_Med_1524.pdf	936112 38bbb35a025ee0a5bdddaf7b7cf4014106 49cb	no	7
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	HACKING_J_Infection_18.pdf	694344 e6c30d39bb88528f0a41a660c1fb5fab8a06 7e53	no	7
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	HALL_N_Engl_J_Med_1343.pdf	474755 f6a15f8fdee119bd3d79fdd9eea566b0f9ac 9ab8	no	5
<b>Warnings:</b>					
<b>Information:</b>					
6	NPL Documents	HALL_N_Engl_J_Med_393.pdf	437799 12375b996479f59e39eaf1353e91fc6f357b d3ad	no	4
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	HALL_N_Engl_J_Med_1443.pdf	587626 6f686cfe925ba799681fee0d6fee9a9a226a df1d	no	6
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	HALL_JAMA_3047.pdf	639680 ad15d576ca4efc4b234de822da23c54f528c 8b0a	no	6
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	HALL_Pedi_Inf_Dis_1653.pdf	5635069 787427a5b96e5dbe0f51b0be95633ec55fb 39a0a	no	26
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	HALL_Pediatrics_92.pdf	2283133 a34c29295439ae4249fd33cd0ee209969dc 9d0e0	no	14
<b>Warnings:</b>					
<b>Information:</b>					

11	NPL Documents	HALL_Princ_Pract_Infect_Dis_1501.pdf	2637040 7c9327b3b1a3cd1f1df175176ae09940f5f70086	no	21
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	HEARD_Mol_Med_35.pdf	1254532 160a8ca5e07de2d67919663ba39565af67e8f115	no	11
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	HEFTA_Immunotech_49.pdf	955568 3b3e43fc1ad2c3d56362ff879b18228eed88165a	no	9
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	HEMMINGJ_Infect_Dis_1083.pdf	441225 a3e7b846d29aeb1fa8cc7e41788a1ba4265d7126	no	5
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	HEMMING_Clin_Use_of_Intra_lmmunogl_285.pdf	1148864 0fec47ece3428d180d3c3c0fe36a7fc67ea5dc9f	no	12
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	HENDERSON_N_Engl_J_Med_530.pdf	522014 10dffff45407411405f6a7ddcc6eab94499054c5	no	5
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	HERTZ_Medicine_269.pdf	1263465 30941e87a2dae1061abd0f70f8b08c2c70ba7060	no	13
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	KIM_Am_J_Epidemiol_422.pdf	1432264 4865a515c08d5ae8f80869a21a7c7fac6d6eb368	no	13
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	KUNKEL_Meth_Enzymol_367.pdf	1583006 8e31bb4d371ecf9ff878688f2cb9d02d90c96d9c	no	16
<b>Warnings:</b>					
<b>Information:</b>					

20	NPL Documents	LAM_Prop_Int_Symp_Cont_Rel _Bioact_Mat_759.pdf	160226 5b56c9a6a96d1af2a97bb033e28285fe62ef 6c15	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			24324475		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b>New Applications Under 35 U.S.C. 111</b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b>National Stage of an International Application under 35 U.S.C. 371</b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b>New International Application Filed with the USPTO as a Receiving Office</b> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					